DRG SUCCESSFULLY EXHIBITS AT MEDLAB DUBAI 2018!
The DRG Group recently exhibited at the largest healthcare exhibition & congress in the Middle East: MEDLAB DUBAI from February 5 – 8, 2018 with great success!
In addition to the presentation of several new assays DRG offered live demonstrations of our fully automated random access analyzer: DRG:HYBRiD-XL®. Visitors from around the world gathered to receive personalized presentations of the Hybrid-XL instrument and DRG also displayed our newest ELISA kits like DHT-optimized (DiHydroTestosterone) and Hepcidin 25 (bioactive) High Sensitive ELISA kit.
Several new tests have been added to the DRG:Hybrid-XL in the past few months, including beta hCG, Free Estriol, and TM-CA 72-4. Development is ongoing to expand the Hybrid-XL test panel in the autoimmune segment.
The DRG Group thanks all attendees for their ongoing support and interest! If you are interested in becoming an authorized DRG:HYBRiD-XL® distributor in your territory, please contact Gregory Guest at [email protected] for more information.
Latest posts by Gregory C. Guest (see all)
- NEW AMH (Anti-Mullerian Hormone) ELISA Available at DRG! - May 14, 2018
- DRG SUCCESSFULLY EXHIBITS AT MEDLAB DUBAI 2018! - February 28, 2018
- DRG distributor “SERION-BRAZIL” successfully attends Brazilian Laboratory Medicine Exhibition in Sao Paulo, Brazil - November 22, 2017
News and Updates
DRG is proud to announce a new AMH ELISA (EIA-6053), a quantitative and sensitive ELISA for the measurement of Anti Müllerian Hormone. AMH testing by Disease State Primary ovarian insufficiency Neonatal gender determination Cryptorchidism Testicular...read more
DRG distributor “SERION-BRAZIL” successfully attends Brazilian Laboratory Medicine Exhibition in Sao Paulo, Brazil
DRG is proud to announce the new partnership with Serion-Brazil and looks forward to a longstanding and successful business relationship! Mr. Gustavo Ruales, DRG International's Latin American Sales Manager, also attended the exhibition to support...read more
We are proud to announce the launch of a new assays for DRG:HYBRiD-XL®: TM-CA 72-4. Clinical Application: Tumor Marker (gastrointestinal cancer) Tumor Marker (ovarian cancer) CA 72‑4 is the marker of choice for the therapeutic monitoring and follow-up...read more